Piper Sandler lowered the firm’s price target on Idexx Laboratories to $520 from $600 to reflect updated multiple and estimates. The firm keeps a Neutral rating on the shares following quarterly results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Idexx Laboratories cuts FY24 EPS view to $10.31-$10.59 from $10.82-$11.20
- Idexx Laboratories reports Q2 EPS $2.44 , consensus $2.88
- Idexx Laboratories (IDXX) Q2 Earnings Cheat Sheet
- Lululemon downgraded, Birkenstock upgraded: Wall Street’s top analyst calls
- Idexx Laboratories initiated with a Buy at BTIG